Apel­lis’ ex­pan­sion plans in­to ALS face road­block

Apel­lis Phar­ma­ceu­ti­cals has stopped the open-la­bel ex­ten­sion por­tion of a clin­i­cal tri­al test­ing its drug pegc­eta­coplan, ap­proved in var­i­ous forms for two oth­er in­di­ca­tions, in pa­tients with ALS.

Tri­al in­ves­ti­ga­tors were test­ing whether a sys­temic ver­sion of the drug could help pa­tients with the neu­rode­gen­er­a­tive dis­ease, but a da­ta mon­i­tor­ing com­mit­tee has said fur­ther treat­ment is not war­rant­ed af­ter an un­blind­ed re­view pro­vid­ed new in­sight, an Apel­lis spokesper­son con­firmed to End­points News in an emailed state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER